HISTON DEACETYLASE INTAMPER FOR USE IN IMMUNOTHERAPY
DE602017092576T2Active Publication Date: 2025-11-05VIRACTA SUBSIDIARY INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602017092576
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-07-15
- Filing Date
- 2017-07-14
- Publication Date
- 2025-11-05
- Estimated Expiration
- 2037-07-14
AI Technical Summary
Technical Problem
Immunotherapies for cancer and viral infections are ineffective against latent viral infections due to the lack of expression of viral proteins on the cell surface, and existing antiviral drugs like ganciclovir are ineffective without lytic phase viral protein expression.
Method used
Administering a histone deacetylase inhibitor (HDACi) like CHR-3996 to induce expression of viral proteins or antigens in latent virus-infected cells, combined with immunotherapies such as vaccines, antibodies, or T-cell therapies, to enhance the immune response against cancer cells.
Benefits of technology
Enhances the efficacy of immunotherapies by increasing the visibility of viral antigens, allowing immune cells to target and destroy cancer cells associated with latent viral infections.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.